The vogue for the determination of immune complexes (ICs) in the clinical setting has now passed, as can be seen from the fact that only two of the regional immunology reference laboratories in the UK still offer a service. This is partly due to the lack of speci®city seen in the assays available, which, apart from minor modi®cations, have remained essentially unchanged. They have not lived up to their initial promise and are unlikely to be offered by service laboratories in the future. In this review we consider when these assays may still have a role and which might be the most useful in a particular clinical setting.
An IC is formed when an antibody reacts speci®cally with its corresponding antigen. The size of the complex formed is dependent on many factors, including the ratio of antibody to antigen, the valency of the antigen and the avidity of the antibody±antigen reaction. IC formation is an integral part of the normal immune response to infection and usually takes place without adverse pathological consequences. ICs are captured by speci®c receptors, in particular on erythrocytes, and transported to the reticuloendothelial system for processing and removal. The events leading to IC formation and subsequent removal are summarized in Fig. 1 . There are, however, various disorders in which ICs play an important role in the disease process. These include some forms of vasculitis (e.g. Henoch±SchoÈ nlein purpura), infectious disorders (e.g. bacterial endocarditis, shunt nephritis) and connective tissue autoimmune disorders [e.g. rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)]. The pathology generally arises from inappropriate clearance or deposition of ICs. Thus, vasculitis results from IC deposition in vessel walls, nephritis from glomerular deposits and some forms of arthritis from deposition in the joints.
In the 1970s and 1980s, recognition of the involvement of IC in disease led to the development of a wide variety of methods for their detection, either in the form of`circulating immune complexes' (CIC) in body¯uids, or deposited IC in biopsy tissue. The latter remains a useful diagnostic tool.
DIRECT VISUALIZATION IN BIOPSY TISSUE BY IMMUNOHISTOCHEMISTRY
This technique is of genuine clinical worth. Biopsy tissue sections are stained for the presence of either immunoglobulin (Ig), complement components or speci®c antigen (e.g. DNA in SLE) using speci®c antisera. The antisera may be labelled in one of several ways: immunouorescent, immunoenzyme (usually peroxidase or alkaline phosphatase) or for immuno-electron microscopy. This allows direct visualization of the IC and its site of deposition. The presence of immunoglobulin and complement together is assumed to represent local IC (e.g. IgA and C3 in skin biopsy from dermatitis herpetiformis patients). It should be remembered, however, that not all immunoglobulin detected will represent CIC. Note, for example the direct autoantibody binding of IgG to the glomerular basement membrane in Goodpasture's disease. Figure 2 shows an immuno¯uorescence picture of renal glomerular deposits of ICs in SLE.
DETECTION OF CIC IN BODY FLUIDS (USUALLY SERUM)
At least 40 different assays for CICs have been described. They vary widely in terms of disease sensitivity, speci®city and clinical applicability. Possibly the major area of investigation has been in autoimmune disease, in particular SLE. SLE has been considered the archetypal IC disease. Many of the disease manifestations, including renal disease, arthritis and neurological symptoms, have been attributed to IC, and many of the studies quoted here have attempted to correlate the levels of detectable IC with disease exacerbation. It should be noted in particular that the renal disease in SLE may manifest in several forms (mesangial, membranous, focal or diffuse proliferative) and that these are often simply lumped together as`lupus nephritis'. Further,`disease exacerbation' may mean a worsening of any aspect of the disease ± renal, cerebral, joint or cutaneous.
We will summarize the principles and advantages of some of the more robust of these assays. Broadly, they fall into three groups. First, there are those that utilize physical properties such as size or cryoprecipitability. Second, there are those that utilize biological properties of the IC, such as the ability to bind to speci®c receptors on cultured cells (e.g. the Raji cell assay). Third, one can look indirectly for secondary effects of ICs, such as the consumption of complement components.
All assays for CIC require good sample collection. Ideally, samples should be collected into a plain glass tube, without clot activator. These should be allowed to clot and then separated at 37 Ê C. Transfer of samples from the patient to the laboratory should be standardized and as rapid as possible. Serum samples should be stored in aliquots at 3 70 Ê C. Repeated freezing and thawing must be avoided as this will aggregate IgG and lead to false positives in many CIC assays. Similar precautions are necessary in the separation of serum for the investigation of cryoglobulinaemia. Failure to follow these principles may lead to loss of the cryoprecipitate during its isolation. In contrast to other investigations for CIC, the serum is cooled to 4 Ê C, rather than frozen at 3 70 Ê C, prior to analysis. In most cases a precipitate will form in the ®rst 24 h but may take up to 72 h. By de®nition, the cryoglobulin should fully redissolve on rewarming to 37 Ê C. Failure to do so suggests the presence of artefactual debris. Unless the possible presence of cryo®brinogen is being speci®cally investigated, plasma should not be used.
The temperature at which the cryoprotein precipitates may be of theoretical interest (`thermal pro®ling'). A cryoprotein that precipitates at 22 Ê C is more likely to cause signi®cant clinical problems than one precipitating at 4 Ê C.
However, in practice, patients are almost invariably symptomatic at presentation and thermal pro®ling does not normally help in the diagnosis or management of cryoglobulinaemia.
PHYSIOCHEMICAL DETECTION METHODS FOR CICs
Cold precipitation/cryoglobulin detection This is a relatively insensitive but nevertheless very useful method for detecting ICs. Complexed immunoglobulins that precipitate in the cold are called cryoglobulins. Not all cryoprecipitable immunoglobulin is attributable to ICs. Brouet et al. established a working classi®cation as long ago as 1974. 1 In brief, there are three types of cryoglobulins (Table 1 ). Type I are monoclonal immunoglobulins, usually associated with myeloma or macroglobulinaemia. These are actually immune aggregates rather than ICs, because precipitation does not depend on interaction with an antigen but solely on the innate insolubility of the protein itself. Types II and III are both the result of rheumatoid factor (RF) activity, usually IgM anti-IgG. In the case of type II, the RF is monoclonal and in type III it is polyclonal. Thus types II and III are the result of true IC formation in which the antigen is autologous IgG. Cases often arise after infection [e.g. hepatitis C virus (HCV)], or complicating autoimmune disease, especially connective tissue diseases such as SLE. Treatment of the underlying disorder may lead to resolution of the cryoglobulin. Type I and type II cryoglobulins almost invariably cause symptoms. Type III less frequently have a direct role in disease pathology. The presence of a cryoglobulin indicates the need to fully investigate the patient for the presence of lymphoreticular neoplasia. Cryoglobulins contribute to the pathology of the disease, often leading to hyperviscosity syndrome and vasculitis. Other manifestations of IC disorders may also be seen (e.g. glomerulonephritis). The detection of a cryoglobulin should thus prompt the further investigations shown in Table 2 .
Quanti®cation of the cryoprecipitate may be useful in monitoring therapy ( Fig. 3 ). This may be done either by simple measurement of the precipitate as a percentage of serum volume (thè cryocrit') or by redissolving the precipitate at 37 Ê C and assaying the protein content. If the cryoglobulin concentration is high, it may also be possible to quantify it by subtracting the amount of supernatant immunoglobulin from the total amount in the original sample.
The patient whose data are shown in Fig. 3 had an overlap syndrome that included features of SjoÈ gren's disease and lupus. Acute renal dysfunction led to investigation for and detection of the cryoglobulin, and treatment included prednisolone and cyclophosphamide. Stopping the cyclophosphamide after day 150 led to relapse. Note that the high level of IC led to complement consumption and reversible lowering of the C4 concentration, which therefore provided an alternative marker of disease activity in this patient. This is a pattern we ®nd quite commonly in patients with cryoglobulinaemia.
Analysis of the accumulated data from many studies has shown type II cryoglobulinaemia to be strongly associated with HCV infection (e.g. Miescher et al. 2 ). Agnello et al. reported that anti-HCV antibodies and almost all the viral RNA were concentrated in the cryoprecipitate. 3 Conversely, Hartmann et al. showed that 28/55 (51%) patients with chronic HCV infection had cryoglobulinaemia (mean cryocrit 2´2%). 4 In this study few were typed, but both type II and type III cryoglobulins were found. Similarly, Lunel et al. found 69/127 (54%) patients with HCV hepatitis to have cryoglobulinaemia (22 256 Lock and Unsworth Ann Clin Biochem 2000: 37 type II, 47 type III). 5 Importantly, Pozzato et al. detected a high prevalence (9/31; 29%) of lowgrade non-Hodgkin's lymphoma in HCVassociated type II cryoglobulinaemia. 6 Initial response to interferon therapy in type II cryoglobulinaemia is usually good. However, fewer than 25% of patients achieve long-term remission with standard therapy. 7±9 It should be noted that, although HCV is the predominant disease association in hospital inpatients with type II cryoglobulinaemia, it is not the only cause. An association with hepatitis B virus (HBV) is well known. 10 Critical review 11 has reduced the emphasis of this ®nding, with cryoglobulinaemia being less frequent in HBV than early studies might suggest. Lunel et al., for example, found cryoglobulins in 15% of 40 patients with HBV. 5
Separation/measurement on the basis of IC molecular weight
The polyethylene glycol (PEG) precipitation assay High molecular weight compounds will precipitate ICs from solution by the principle of exclusion. The most popular of these compounds for this purpose is polyethylene glycol (PEG), which is usually added to a ®nal concentration of 2±3%. The assay, which includes an overnight cold precipitation step, may also detect cryoprotein, even in samples that have been separated at room temperature (personal observation). The PEG precipitation assay is simple in principle, and analysis of the component parts of the precipitate, by enzyme-linked immunosorbent assay (ELISA) or nephelometry, may yield additional speci®city. Valentijn et al. applied this approach to SLE patients. 12 Increases in PEG-precipitable IgG or C3 showed a high speci®city for disease exacerbation (84% and 99%) but with a low sensitivity (9% and 3%). Further, Coppo et al. did not ®nd PEG precipitation a useful predictor of disease change in patients with lupus nephritis. 13 The assay is relatively simple to perform and commercial assays are available. It should be noted that monomeric IgG is also precipitated in small amounts, even from normal serum. This interference by monomer is made worse by hypergammaglobulinaemia, 14 which is common in autoimmune disorders (e.g. SjoÈ gren's syndrome).
Sucrose density centrifugation
Sucrose density centrifugation, with or without subsequent immunochemical analysis of the high
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Ann Clin Biochem 2000: 37 molecular weight fractions isolated from serum proteins, is very time-consuming and, although useful as a research tool, is not suitable for use in the diagnostic laboratory, where there is a need to process many samples.
DETECTION BASED ON BIOLOGICAL PROPERTIES OF CICs

Binding of complement added in vitro
C1q binding assays C1q is the ®rst component of the classic pathway of complement. C1q binding assays use the high functional af®nity of C1q for conformationally altered immunoglobulin Fc regions, as found in CIC, to distinguish between free and complexed immunoglobulins. C1q binds weakly to monomeric IgG and IgM, but binding is enhanced when these proteins form physical aggregates. C1q-based assays detect only complexes activating the classic complement pathway. C1q binding assays are designed either as¯uid-phase or solid-phase assays. Fluid-phase assays (C1qFP) generally use 125 I-labelled C1q in the ®rst stage and PEG to precipitate out the complex, as described by Zubler et al. in 1976 . 15 The solid-phase C1q binding assay (C1qSP) originally used C1q-coated plastic tubes to capture CIC and radiolabelled anti-IgG for detection. 16 ELISA modi®cations are now more popular and are commercially available. Although they are based on similar principles, the two assays are not equivalent. 17 In lupus nephritis these assays consistently give higher results than in patients with inactive disease. 14, 18 However, Valentijn et al. found that rises in C1qFP had a low sensitivity and speci®city for disease exacerbation in lupus (36% and 29%, respectively), resulting in a positive predictive value of only 51%. 12 Abrass et al. claimed a positive predictive value of 82% for disease exacerbation in SLE when the C1qFP went from negative to positive. 19 Coppo et al. reported that only 50% of their patients showed an increase in C1qFP prior to clinical exacerbation. 14 In contrast, they found that, in lupus nephritis, a rapid drop in C1qSP on treatment was a good prognostic feature and that this preceded recovery in serum complement levels.
Several substances may interfere with these assays. C1q may bind polyanions (e.g. DNA, lipopolysaccharide),which can affect¯uid-phase assays. 20 C1qSP assays avoid these problems but RF can interfere instead. More recently, possible interference from anti-C1q autoantibodies 21, 22 has been described.
Detection of previously bound IC-associated complement
Conglutinin-binding assays Conglutinin, a 750-kDa protein found in some ruminants, including cattle, binds to the high mannose group of the inactivated complement component C3bi. As such it is a C-type lectin. Conglutinin-binding assays utilize this calciumdependent C3bi-binding property of conglutinin to isolate ICs. Such assays were ®rst described in 1977 as solid-phase assays. 23, 24 Conglutinin is used as the capture phase in an ELISA. The complex is detected by means of anti-immunoglobulin. Like the C1q-binding assay, this assay is prone to interference, in particular from anti-collagen II antibodies. 25 As these antibodies are frequently found in connective tissue diseases, 26 the utility of the assay is restricted. One study has advocated the use of the ratio of calciumdependent to calcium-independent binding to overcome the interference from conglutininbinding antibodies. 27 Although popular in other countries, this assay has not been widely used in the UK.
The Raji cell assay
The Raji cell (derived from a B-lymphoblastic Burkitt lymphoma) assay uses the CR2 complement receptors found on this cell line to detect C3bi bound to ICs. Although one of the better assays, it has never been widely available in the UK. The major disadvantage is the need to use living cells. Anti-lymphocyte antibodies may interfere with the assay, 28 as may anti-DNA. 29 A commercial alternative (the Raji Cell Replacement Assay) is available, which uses monoclonal antibody to C3 conversion products as the capture phase. This assay has been used to study nephritis in SLE. 30 CIC levels were found to be four times higher in proliferative glomerulonephritis than in membranous glomerulonephritis.
Antiglobulin assays
These assays rely on the property of RF, usually monoclonal, to interact strongly with aggregated IgG but only weakly with monomeric IgG. These assays differ from many others in being able to detect non-complement-binding ICs. Originally described as a radioimmune inhibition assay, 31 solid-phase assays have also been described. 32 Although functionally one of the better methods, the antiglobulin method has not found widespread application. It has been used in the investigation of autoimmune disorders. 31, 33 High levels of monomeric IgG and intrinsic RF may interfere.
INDIRECT ASSAYS: COMPLEMENT CONSUMPTION OR ACTIVATION
These assays rely on various methods for the assessment of complement activation.
C3/C4
Monitoring C3 and C4 levels in SLE has been used as an indicator of disease activity for many years. For example, in 1977, Davis et al. 34 noted that a fall in C4 levels tended to precede a fall in C3 levels. The authors found that, in some cases, complement levels were a more sensitive indicator of clinical change than the titre of antidouble-stranded DNA antibody. This approach is not applicable to all cases of SLE. Some SLE patients have a pre-existing C4 de®ciency or, more commonly, a partial C4 de®ciency; thus, C4 may be permanently low, even in periods of remission.
Miescher et al. showed low C4 to be a consistent ®nding in HCV-associated cryoglobulinaemia (15/15 patients). 2 Hypocomplementaemia is a frequent ®nding in cryoglobulinaemia. This may in part be due to chronic activation in vivo, but is aggravated by IC-mediated activation in vitro. 35 Figure 3 also illustrates the use of C4 to monitor a patient with type II cryoglobulinaemia. Note that C4 is faster and easier to measure than cryoglobulinand that its level falls prior to the rise in cryoglobulin in the relapse episode.
Measurement of C3 and C4 may thus be a mirror for the activity of ICs. It should be remembered, however, that there are other in¯uences on C3 and C4 levels, not least the involvement of complement in acute-phase response. C3, C4 and other complement components may be elevated as part of the acute-phase response. There may therefore be forces working in opposite directions to in¯uence the overall levels detectable in the serum.
In vitro complement consumption assay
This assay, also called anti-complementary activity, measures the ability of ICs to bind and activate complement, thus reducing the amount of functional complement remaining available for erythrocyte (sheep) lysis in haemolytic assays. 36 Interfering substances include Creactive protein, heparin and DNA, alternative pathway activators (e.g. endotoxin) and certain enzymes (e.g. plasmin). 37 Furthermore, in order for the assay to operate, it is necessary to heatinactivate intrinsic complement completely in the test samples at 56 Ê C. This may lead to aggregation of immunoglobulin and false positive results. Interestingly, in a patient with C2 de®ciency and SLE, this assay showed good correlation with other immunological measures of IC activity (complement levels, CIC by a capture ELISA, C3d), but could not be directly correlated with clinical activity. 38 In the study of Davis et al., ICs were associated with high DNA binding and active disease, but many patients with clinically active disease had no detectable ICs. 34 Total haemolytic complement (CH 50 ) CH 50 is a functional complement test based on the ability of the patient's complement to lyse IgG-coated sheep erythrocytes. Titration allows calculation of the amount of serum needed to achieve 50% lysis by spectrophotometry. It is envisaged that, in the presence of ICs, complement will be consumed in vivo. Thus, a low CH 50 would indicate the presence, and a high or normal CH 50 the absence, of ICs. Arguably, the use of CH 50 as a measure of ICs is ill-advised. The need for fresh samples is even more important here than in other IC assays and artefacts of sample decay are common. Furthermore, de®ciency of any of the complement components will result in a low CH 50 , such as the C4 de®ciency frequently seen in SLE. Despite this, some favour its use as part of a panel for monitoring SLE. It is lowest in patients with renal involvement. 39
ANTIGEN-SPECIFIC ASSAYS
Several studies have sought to identify the antigens involved in ICs in certain diseases, but not all of these have been successful. For example in 1977, Izui et al. found that, although 52% of SLE patients had CIC, only 6% had DNA/anti-DNA complexes. 40 The wide diversity of antigens potentially involved in IC disease makes it unlikely that this approach will ever be widely used; thus the approach is limited to research only.
THE PROBLEM OF DISEASE NON-SPECIFICITY
Several groups have shown that no single assay shows good discrimination across different IC diseases. The World Health Organization (WHO) study (1978) 33 exempli®es the problem (see Table 3 ).
STANDARDIZATION AND QUALITY CONTROL
Standardization of IC assays is a major problem. The most frequently used standard is heataggregated IgG, which has the advantage of being relatively simple to make. However, it does not correspond to a physiological complex. In 1984, a standard IC composed of tetanus and anti-tetanus in de®ned proportions was proposed. 41 This promising approach does not appear to have been taken forward.
There is no UK National External Quality Assurance Scheme for ICs.
FINAL COMMENT
The early enthusiasm for the detection of CIC has to a large extent waned, primarily because the use of non-antigen-speci®c tests yields very little of diagnostic value. The view expressed by the WHO in 1988 42 ±`The detection of immune complexes is not essential in any clinical condition' ± remains unchallenged in 1999. C1q binding  78  76  83  74  70  C1q solid phase  58  53  25  18  30  Raji cell  91  65  71  89  20  Conglutinin  44  55  33  65  10 From Lambert et al. 33 Published with permission. RA=rheumatoid arthritis; SLE=systemic lupus erythematosus.
